{"filings":[{"id":1536077,"accession_number":"0001104659-26-082116","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-07-09T12:35:31+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MetaVia completes dose titration in Phase 1 Part 3 of DA-1726 obesity trial; topline data on track for Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All active patients in Part 3A (48 mg) and Part 3B (64 mg) reached highest target doses after titration.","Prior Phase 1 MAD data showed 9.1% mean weight loss at 48 mg in 8 weeks, plus reductions in waist circumference and glycemic measures.","Part 3 enrolls ~40 obese subjects randomized 4:1 active:placebo across two 16-week titration cohorts.","Topline data from Part 3 remains on track for release in Q4 2026.","CEO cites favorable tolerability and efficient titration as potential competitive advantage over marketed obesity therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1414996,"accession_number":"0001104659-26-080316","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-07-02T20:06:39+00:00","items":["8.01","9.01"],"status":"ready","headline":"MetaVia files prospectus supplement for up to $4M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 2, 2026, MetaVia filed a prospectus supplement for an at-the-market offering of up to $4,000,000 of common stock.","The offering is under a Sales Agreement with Ladenburg Thalmann & Co. Inc. dated November 6, 2025.","Honigman LLP issued an opinion on the validity of the shares to be issued, filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":917919,"accession_number":"0001104659-26-071358","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-06-08T20:00:57+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"MetaVia stockholders approve reverse stock split (1:5–1:22) and 200,000-share equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split at ratio in range 1-for-5 to 1-for-22; Board to determine final ratio.","Equity incentive plan amended to increase authorized shares by 200,000, effective upon stockholder approval.","Elected D. Gordon Strickland and James P. Tursi, M.D. as Class I directors for three-year terms.","Ratified BDO USA, P.C. as independent registered public accounting firm for fiscal year ending Dec 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":901156,"accession_number":"0001104659-26-071211","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-06-08T13:01:47+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MetaVia DA-1726 48mg cohort achieves 9.1% weight loss at Day 54; vanoglipel combo shows synergy in MASH/T2D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DA-1726 Phase 1 48mg cohort: 9.1% mean weight loss at Day 54 (p<0.05 vs placebo), no plateau observed.","Waist circumference reduced by 9.8 cm at Day 54; BMI reduced by 3.4 kg/m².","Vanoglipel + resmetirom in MASH mouse model: 23.6% weight loss vs control, ALT reduction 83.5%.","Vanoglipel + metformin in T2D model: 16.3% weight loss, 28.7% non-fasting glucose reduction.","Phase 1 Part 3 titration studies for higher-dose DA-1726 ongoing; results expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":678276,"accession_number":"0001104659-26-066631","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-05-27T13:01:19+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia announces Phase 1 data: DA-1726 48 mg yields 9.1% weight loss at Day 54 without plateau","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["48 mg cohort achieved 9.1% mean body weight reduction at Day 54; no plateau through Week 8.","Exploratory FibroScan showed liver improvements: CAP -20.0 dB/m vs +24.0 placebo; liver stiffness -10.3% vs +13.8%.","No serious adverse events or treatment-related discontinuations; GI events mild-to-moderate and transient.","Waist circumference reduced by 9.8 cm at Day 54 (p<0.05 vs placebo at Day 26).","Ongoing Phase 1 Part 3a/3b titration studies evaluate extended treatment at higher doses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":483116,"accession_number":"0001104659-26-063059","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-05-18T13:01:28+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia announces three late-breaking abstracts accepted for ADA 2026 poster presentations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DA-1726 (GLP-1/glucagon dual agonist) Phase 1 Part 3 titration study data expected Q4 2026.","Vanoglipel (GPR119 agonist) preclinical combo data with resmetirom for MASH and metformin for T2D.","Presentations at ADA 2026 in New Orleans, June 5-8; posters available after event.","CEO notes DA-1726 potential as differentiated obesity treatment; vanoglipel broad liver/metabolic therapeutic potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442568,"accession_number":"0001104659-26-061148","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-05-14T20:06:05+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"MetaVia Q1 net loss $3.8M; Phase 1 Part 3 dosing started for DA-1726","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.8M ($0.79 per share) vs $3.7M ($3.93 per share) in Q1 2025.","Cash and cash equivalents $13.7M as of March 31, 2026, sufficient into Q4 2026.","First patient dosed in Phase 1 Part 3 16-week titration study of DA-1726; data expected Q4 2026.","January 2026 public offering raised ~$9.3M gross proceeds to fund operations.","R&D expenses $2.1M, G&A $1.9M; total operating expenses $4.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":23,"accession_number":"0001104659-26-058332","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-05-11T13:01:36+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia DA-1726 late-breaking abstract accepted for EASL 2026 poster; Phase 1 data expected Q4","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abstract LB26-5204 on DA-1726 (GLP-1/glucagon dual agonist) accepted for poster at EASL Congress 2026 in Barcelona (May 27-30).","Poster title: Safety, Tolerability, PK, PD of DA-1726 in higher-dose Phase 1 cohort with exploratory liver assessment.","Phase 1 Part 3 titration study ongoing; optimizing higher dose levels and tolerability; data expected Q4 2026.","Presenting author: Chris Fang, CMO; poster available on MetaVia website after presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94299,"accession_number":"0001104659-26-041784","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia doses first patient in higher-dose Phase 1 study of DA-1726 for obesity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Part 3 of Phase 1 evaluates one-step (16→48 mg) and two-step (16→32→64 mg) titration over 16 weeks in 40 obese adults.","Previously reported ~9% weight loss at 48 mg dose with favorable tolerability; glycemic and liver benefit signals.","Data from Part 3 expected in Q4 2026; primary endpoints are safety and tolerability.","DA-1726 is a dual GLP-1/glucagon (OXM) analog; company aims for differentiated efficacy and simpler titration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106549,"accession_number":"0001104659-26-035238","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia posts updated corporate presentation on IR website; full content not in excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation posted to MetaVia's IR website on March 26, 2026.","Presentation highlights company's strategy for transforming cardiometabolic diseases.","No financial, clinical, or pipeline details available from the provided excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106548,"accession_number":"0001104659-26-034907","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MetaVia reports FY2025 net loss $13.0M; DA-1726 Phase 1 shows 9.1% weight loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.0M ($7.35/share) vs $27.6M ($39.13/share) in FY2024; revenue not reported.","Cash and cash equivalents $10.3M at Dec 31, 2025; with Jan 2026 $9.3M offering, funds operations into Q4 2026.","DA-1726 48 mg Phase 1 data: 9.1% weight loss, reduced waist circumference, improved glucose and liver stiffness.","Phase 1 Part 3 titration study (48 mg and 64 mg) IRB approved; dosing starts April 2026, data expected Q4 2026.","Vanoglipel Phase 2a MASH data presented at AASLD; end-of-Phase 2 FDA meeting being scheduled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106547,"accession_number":"0001104659-26-029912","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MetaVia (MTVA) IRB approves Phase 1 Part 3 trial of DA-1726 at 48 mg and 64 mg doses","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Phase 1 Part 3 trial will enroll 40 obese adults across two 16-week titration cohorts randomized 4:1.","Part 3A tests one-step titration to 48 mg; Part 3B two-step to 64 mg; primary endpoints safety/tolerability.","Initial dosing expected April 2026; data readout expected Q4 2026.","CEO cites prior 48 mg cohort results: ~9% weight loss, improved glycemic control, favorable safety profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106546,"accession_number":"0001104659-26-006976","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MetaVia discloses FY2025 discretionary bonuses for CEO and CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Hyung Heon Kim received $239,862 bonus, total comp $756,328 (2024: $716,404).","CFO Marshall Woodworth received $157,320 bonus, total comp $562,985 (2024: $774,699).","Bonuses were approved Jan 23, 2026; no equity awards for either executive in FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106545,"accession_number":"0001104659-26-004532","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"MetaVia closes $9.3M public offering with full over-allotment; net proceeds ~$7.7M for DA-1726","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed offering of 3,005,574 shares/equivalents + 4,508,361 Series C and Series D Warrants at $3.10 each.","Net proceeds to MetaVia approximately $7.7 million after underwriting discounts and expenses.","Series C Warrants ($3.10 exercise, 5-year term); Series D Warrants ($3.10 exercise, 2-year term, callable).","Series D Warrants callable after positive Phase 1b Part III data for DA-1726 and stock price >$4.65 for 20 days.","Proceeds to fund working capital and clinical development of DA-1726 for obesity treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106544,"accession_number":"0001104659-26-000736","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"MetaVia reports preliminary cash $10.3M, no debt as of Dec 31, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited cash and equivalents of approximately $10.3 million as of Dec 31, 2025.","No outstanding debt as of year-end 2025.","Complete financial results for FY2025 expected in March 2026; no revenue or EPS disclosed.","Preliminary estimates subject to finalization; company cautions against reliance."],"consensus_eps_estimate":-1.2674,"consensus_eps_actual":-7.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106543,"accession_number":"0001104659-26-000432","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia reports positive Phase 1b results for DA-1726; 9.1% weight loss by Day 54","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Statistically significant 9.1% weight loss (21.2 lbs) and 9.8 cm waist reduction by Day 54 in Phase 1b MAD cohort.","Liver stiffness reduced 23.7% by Day 54 via VCTE, indicating direct hepatic effect.","Fasted glucose improved 12.3 mg/dL from baseline of 105.3 mg/dL; prediabetic subject HbA1c dropped from 6.0% to 5.5%.","No treatment-related discontinuations; GI events mild to moderate.","Plans 16-week titration studies to 48 mg and 64 mg; results expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122886,"accession_number":"0001104659-25-123099","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MetaVia regains Nasdaq minimum bid price compliance; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice Dec 19, 2025 confirming compliance with minimum bid price rule.","Compliance achieved as closing bid price was $1.00+ for 10 consecutive business days Dec 5–18.","Company previously non-compliant since May 29, 2025; had been granted extension to May 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122885,"accession_number":"0001104659-25-117540","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["3.03","5.03","7.01","8.01","9.01"],"status":"ready","headline":"MetaVia announces 1-for-11 reverse stock split effective Dec 4, 2025 to meet Nasdaq listing requirements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-11 ratio effective 5:00 p.m. ET Dec 4, 2025; begins split-adjusted trading Dec 5.","Outstanding shares reduced from ~25.4 million to ~2.3 million; authorized shares unchanged at 100 million.","Options, RSUs, and warrants adjusted proportionately; fractional shares rounded down for cash payment.","Approved by stockholders on June 30, 2025; board set ratio; new CUSIP 64132R 503; symbol remains MTVA.","MetaVia is a clinical-stage biotech focused on cardiometabolic diseases; no financial results reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122884,"accession_number":"0001104659-25-116456","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"MetaVia receives Nasdaq extension to May 2026 to regain minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received Nasdaq approval for 180-day extension to May 26, 2026 to cure bid price deficiency.","Stock closed below $1.00 for 30+ days; compliance deadline originally Nov 25, 2025.","Stockholders previously approved reverse stock split at ratio between 1:5 and 1:30.","If not compliant by May 26, 2026, Nasdaq may delist; company may appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122883,"accession_number":"0001104659-25-108179","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MetaVia Phase 2a vanoglipel shows HbA1c -0.54%p, ALT reductions in MASH trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At Week 16, vanoglipel monotherapy reduced HbA1c by 0.54%p and combination therapy by 0.66%p from baseline 6.99% (p<0.05 vs placebo).","Vanoglipel significantly decreased plasma ALT in patients with baseline ALT 40-200 U/L, with hepatoprotective effects driven by monotherapy.","Improvements in liver steatosis (CAP), stiffness (VCTE), and non-invasive scores (FAST, NIS-4) were observed at 16 weeks.","Circulating biomarkers of cell death (CK18F/M30), inflammation (hs-CRP, CCL2), and fibrosis (TIMP1) were reduced.","Vanoglipel 100 mg reduced pathogenic glycerolipids and glycerophospholipids; well tolerated with no discontinuations except one placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122882,"accession_number":"0001104659-25-107790","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MetaVia posts corporate presentation showing ticker change from NRBO to MTVA","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation posted to company website on November 6, 2025.","Presentation references a prior December 2023 deck under former ticker NRBO.","Current ticker is MTVA; company now branded as MetaVia Inc.","No financial data, guidance, or operational updates provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122881,"accession_number":"0001104659-25-107447","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MetaVia reports Q3 net loss $3.4M, cash $14.3M; DA-1726 48mg cohort data due by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.4M ($0.14 per share) vs $5.7M ($0.55) in Q3 2024; cash $14.3M expected to fund into 2026.","R&D expenses fell to $1.9M from $4.5M YoY; total operating expenses $3.5M.","Dosed first patient in 8-week 48mg MAD cohort of DA-1726 for obesity; top-line data expected by year-end 2025.","Phase 1 DA-1726 data: 6.3% mean weight loss, 3.9-inch waist reduction, PK supports once-weekly dosing.","Vanoglipel (DA-1241) Phase 2a showed reductions in liver fat, inflammation, fibrosis; end-of-Phase 2 FDA meeting H1 2026."],"consensus_eps_estimate":-2.4908,"consensus_eps_actual":-0.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139585,"accession_number":"0001558370-25-010787","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MetaVia posts updated corporate presentation reflecting new name and ticker change from NRBO to MTVA","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted an updated corporate presentation on its website and as Exhibit 99.1.","Presentation dated August 2025 shows new corporate identity as MetaVia Inc. (MTVA), formerly NeuroBo Pharmaceuticals (NRBO).","Presentation may be used in investor communications; forward-looking statements included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139584,"accession_number":"0001558370-25-010658","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MetaVia Q2 net loss $4.0M; cash $17.6M; DA-1726 48mg data expected Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.0M ($0.26/sh) vs $10.1M ($1.85/sh) in Q2 2024; R&D expenses fell to $2.3M from $8.1M.","Cash $17.6M as of June 30, 2025, expected to fund operations into 2026.","Dosed first patient in 8-week 48mg MAD cohort of DA-1726 for obesity; top-line data due Q4 2025.","Signed AI collaboration with Syntekabio to identify new indications for DA-1241 beyond MASH.","Closed $10.0M private placement in May 2025 with Dong-A ST and Dong-A Socio Holdings."],"consensus_eps_estimate":-3.4782,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139583,"accession_number":"0001558370-25-010415","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia extends Phase 1 DA-1726 48mg MAD cohort to 8 weeks; top-line data Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended 48 mg MAD cohort to 8 weeks from 4; first patient received fifth weekly dose.","Top-line data from the extended cohort expected in Q4 2025.","Prior 32 mg dose data: mean weight loss 4.3% by Day 26, early satiety in 83% of patients.","Waist circumference reduction of up to 3.9 inches by Day 33 at 32 mg dose.","DA-1726 is a dual GLP1R/GCGR agonist for obesity with a 3:1 balanced activation ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139582,"accession_number":"0001558370-25-010031","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia partners with Syntekabio to use AI for new DA-1241 indications","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Collaboration leverages Syntekabio’s DeepMatcher platform to screen >1,700 protein targets for new DA-1241 indications.","Follows positive Phase 2a data in MASH; DA-1241 showed safety, hepatoprotective, and glucose-regulating effects.","No financial terms disclosed; initial insights expected later in 2025.","DA-1241 is a novel oral GPR119 agonist in clinical development for cardiometabolic diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139581,"accession_number":"0001558370-25-009139","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia doses first patient in 48 mg MAD cohort of Phase 1 obesity trial; Q4 top-line data expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in 48 mg multiple ascending dose cohort of DA-1726 (GLP1R/GCGR dual agonist) for obesity.","Prior 32 mg data: mean weight loss 4.3%, max 6.3% at Day 26 (p=0.0005); 83% early satiety; average waist reduction 1.6 inches by Day 33.","Fasting glucose reduced up to 18 mg/dL without hypoglycemia; no QTcF prolongation; mild GI side effects, suggesting favorable tolerability.","CEO stated DA-1726 has best-in-class potential with no titration needed; top-line results from 48 mg cohort expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157163,"accession_number":"0001558370-25-009000","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MetaVia shareholders approve reverse stock split and share issuance to Dong-A Socio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Mark A. Glickman and Michael Salsbury as Class III directors until 2028.","Ratified BDO USA as independent auditor for FY2025; advisory approval of executive compensation.","Approved reverse stock split in range of 1-for-5 to 1-for-30, with final ratio set by board.","Approved issuance of 4,605,162 shares to Dong-A Socio Holdings upon exercise of pre-funded warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157162,"accession_number":"0001104659-25-054976","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"MetaVia receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified MetaVia on May 29, 2025 that its closing bid price was below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until Nov 25, 2025) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, MetaVia may get an additional 180 days if it meets other listing standards; otherwise delisting may follow.","Company intends to monitor bid price and consider options, including a reverse stock split, to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157161,"accession_number":"0001558370-25-008047","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MetaVia posts updated corporate presentation; prior ticker NRBO referenced","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted updated corporate presentation dated May 21, 2025 to its IR website.","Presentation title slide shows prior ticker NRBO (Dec 2023) and current ticker MTVA (May 2025), suggesting a name or ticker change.","No other specific business updates from the limited exhibit text provided; full presentation content not available in this extract."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157160,"accession_number":"0001558370-25-007740","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MetaVia reports Q1 net loss $3.7M; DA-1726 shows 4.3% mean weight loss in Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $11.2M at Q1-end; plus $10M private placement in May, funding into 2026.","Net loss $3.7M ($0.36/sh) vs $6.7M ($1.32/sh) YoY; R&D spend down to $2.3M from $4.9M.","DA-1726 (obesity) mean weight loss 4.3% at 32 mg at Day 26 (p=0.0005); max 6.3%; no titration needed.","DA-1241 (MASH) Phase 2a reduced ALT 22.8 U/L at 16 weeks; end-of-Phase 2 FDA meeting expected H1 2025.","Additional DA-1726 dose cohorts to start Q3 2025; data expected Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157159,"accession_number":"0001104659-25-048210","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"MetaVia raises $10M in private placement; issues shares and pre-funded warrants at $0.71/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$10M from 9.48M shares ($0.71/each) and 4.61M pre-funded warrants ($0.709/each).","Pre-funded warrants exercisable at $0.001 per share after stockholder approval.","Proceeds to fund working capital and clinical development of DA-1726 for obesity.","Ladenburg Thalmann acted as exclusive placement agent; offering closed May 14, 2025.","Company to file resale registration statement within 30 days after stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157158,"accession_number":"0001558370-25-006598","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia Phase 2a DA-1241 hits ALT reduction of 22.8 U/L, CAP score down 23 dB/m in MASH patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DA-1241 100 mg lowered ALT by 22.8 U/L (p<0.05 vs placebo) after 16 weeks in patients with baseline ALT 40-200 U/L.","Liver fat (CAP) reduced 23.0 dB/m with DA-1241 100 mg vs 1.4 dB/m placebo; FAST score dropped from 0.559 to 0.371.","HbA1c decreased 0.54%p at week 16 (baseline 6.99%); in type 2 diabetes subgroup, HbA1c fell 1.08%p.","Inflammation and fibrosis biomarkers (hs-CRP, CCL2, TIMP1) improved significantly (p<0.05 vs placebo).","Well tolerated; no TEAEs leading to discontinuation except one placebo; company plans end-of-Phase 2 FDA meeting H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157157,"accession_number":"0001558370-25-005113","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MetaVia reports dose-dependent weight loss and no CV effects in Phase 1 MAD study of DA-1726","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Clear dose-dependent body weight reduction from 8 mg to 32 mg; BMI change significantly greater vs placebo.","No drug-induced heart rate or QTcF increases up to 32 mg at 4 weeks; mean HR decreased in most cohorts.","Previously reported: max weight loss -6.3% and mean -4.3% at Day 26 for 32 mg; fasted glucose lowered -18 mg/dL.","Additional cohorts to determine maximum tolerated dose; 32 mg likely starting dose for future trials.","All pre-funded warrants exercised for 1,430,000 shares post-announcement; no warrants outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157156,"accession_number":"0001558370-25-004833","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"MetaVia posts updated corporate presentation; pre-funded warrants for 1.43M shares exercised","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Warrants to purchase 1,430,000 shares of common stock exercised on April 15, 2025.","After exercise, 10,084,869 shares outstanding; no pre-funded warrants remain.","Updated corporate presentation posted to investor website; full content not available in filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157155,"accession_number":"0001558370-25-004796","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"MetaVia reports positive Phase 1 MAD data for DA-1726 obesity drug: 6.3% max weight loss, strong glucose control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean weight loss 4.3% (max 6.3%) at 32 mg dose on Day 26 (p=0.0005).","Fasted glucose lowered by mean 5.3 mg/dL (max 18 mg/dL); waist circumference reduced mean 1.6 in (max 3.9 in).","No SAEs or discontinuations; mild GI AEs transient, 83% of 32 mg cohort reported early satiety.","Adding higher-dose cohorts to determine MTD; planning Phase 1 Part 3 in Wegovy early drop-out patients.","Company cites balanced GLP-1/glucagon activation as potential best-in-class profile for safety and efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175512,"accession_number":"0001558370-25-003344","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MetaVia reports FY2024 net loss $27.6M; cash $16.0M funds into Q3 2025; DA-1726 data expected April","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $27.6M ($3.56/share) vs $12.5M ($2.46/share) in 2023; R&D expenses rose to $21.6M from $9.2M.","Cash $16.0M as of Dec 31, 2024 (down from $22.4M); expected to fund operations into Q3 2025.","DA-1726: Top-line data from additional MAD Part 2 cohorts expected April 2025; proof-of-concept study planned Q4 2025.","DA-1241: Phase 2a in MASH met primary endpoint (ALT reduction); full data at medical meeting 2025; FDA end-of-Phase 2 meeting H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175511,"accession_number":"0001558370-25-000100","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia posts corporate presentation with DA-1241 Phase 2a topline data for MASH","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation posted on Jan 10, 2025, includes DA-1241 Phase 2a topline data.","Data to be presented at MASH-TAG 2025; specific results not disclosed in the filing.","Company formerly traded as NRBO; now ticker MTVA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192461,"accession_number":"0001558370-24-016344","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia (MTVA) announces positive Phase 2a top-line results for DA-1241 in MASH patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DA-1241 100mg achieved statistically significant ALT reduction at weeks 4 and 8 (p=0.0159, p=0.0342), near significant at week 16 (p=0.0506).","Statistically significant improvements in CAP score (p=0.0308) and HbA1C (p=0.0179) vs placebo at week 16.","DA-1241 was very well tolerated; no drug-related serious adverse events reported across treatment groups.","Company plans end-of-Phase 2 meeting with FDA in first half of 2025; full data set awaited.","DA-1241 100mg + sitagliptin also showed significant FAST score reduction (p=0.0416)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192460,"accession_number":"0001558370-24-015952","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"MetaVia posts updated corporate presentation reflecting name change to MTVA","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company updated corporate presentation on Nov 29, 2024; replaces Dec 2023 version with Nov 2024 version.","Ticker changed from NRBO to MTVA; company name changed from NeuroBo Pharmaceuticals to MetaVia Inc.","Presentation available on company website; no new financial or operational details disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192465,"accession_number":"0001558370-24-015839","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["5.03","7.01","8.01","9.01"],"status":"ready","headline":"NeuroBo to rename to MetaVia Nov 29; ticker changes to MTVA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NeuroBo Pharmaceuticals changes legal name to MetaVia Inc., effective Nov 29, 2024.","Nasdaq ticker symbol changes from NRBO to MTVA on the same date.","No shareholder vote required; CUSIP and transfer agent unchanged.","Company expects Phase 2a data for DA-1241 (MASH) in Dec 2024 and Phase 1 obesity data in Q1 2025.","June financing of up to $70M ($20M upfront, $50M warrants) provides funding runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192464,"accession_number":"0001558370-24-014760","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroBo Q3 net loss $5.7M, cash $21.7M; positive Phase 1 SAD data for obesity drug DA-1726","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.7M (EPS -$0.55) for Q3 2024 vs. $3.8M net loss ($0.75 per share) in Q3 2023.","Cash at Sept 30, 2024: $21.7M; expected to fund operations into Q3 2025.","Positive top-line data from SAD Part 1 of Phase 1 trial for DA-1726: safe, tolerable, dose-linear PK; additional cohorts exploring MTD.","DA-1241 Phase 2a MASH trial: top-line data expected in December 2024.","Entered joint research agreement with Dong-A ST and ImmunoForge for once-monthly formulation of DA-1726."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192463,"accession_number":"0001558370-24-014184","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroBo completes Phase 2a MASH trial dosing; topline data due December 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient last visit in two-part Phase 2a trial of DA-1241, a GPR119 agonist for MASH.","95 of 109 randomized patients completed dosing across Part 1 (DA-1241 vs placebo) and Part 2 (DA-1241 + sitagliptin vs placebo).","Primary endpoint: change from baseline in ALT at Week 16; secondary endpoints include lipid and safety measures.","Topline data from both parts expected in December 2024; prior Phase 1 showed DA-1241 well tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192462,"accession_number":"0001558370-24-013161","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroBo posts updated corporate presentation for October 2024 without specific material news","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Posted updated corporate presentation on October 7, 2024, at the company's website.","Presentation dated October 2024, replaces prior December 2023 version.","No specific financial or operational updates disclosed in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208936,"accession_number":"0001558370-24-013080","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroBo reports positive Phase 1 SAD data for DA-1726 obesity drug; no serious AEs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["45 obese participants randomized 6:3 DA-1726 vs placebo; drug safe and well tolerated.","5 AEs in DA-1726 group vs 3 placebo; no serious adverse events reported.","Dose-linear PK observed across investigated range; additional cohorts added to find max tolerated dose.","MAD Part 2 top-line data expected Q1 2025; Part 3 will evaluate early proof of concept.","CEO cites potential best-in-class profile due to balanced GLP1R and glucagon receptor activation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208935,"accession_number":"0001558370-24-012900","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"NeuroBo shareholders approve issuance of shares on warrant exercises at Sep 18 special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 approved: 2,987,855 for, 54,375 against, 71,422 abstentions.","Issuance covers up to 5,089,060 Series A warrants, 7,633,591 Series B warrants, and 127,227 placement agent warrants.","Proposal 2 (adjournment) also approved: 2,997,754 for, 45,209 against, 70,689 abstentions.","Meeting held virtually on September 18, 2024; 3,113,652 shares present or represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208934,"accession_number":"0001558370-24-012137","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"NeuroBo Q2 net loss $10.1M; cash $27.9M; DA-1726 SAD fully enrolled","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2024 $10.1M ($1.85/sh) vs $0.7M ($0.15/sh) Q2 2023; R&D expense rose to $8.1M from $2.4M.","Cash $27.9M at June 30, 2024; expects to fund operations into Q2 2025; closed $20M upfront financing with up to $50M milestone warrants.","DA-1726 SAD Part 1 fully enrolled (45 patients); top-line data expected Q3 2024; MAD Part 2 top-line Q1 2025.","DA-1241 MASH Phase 2a top-line results expected Q4 2024; pre-clinical combination data with semaglutide presented.","Signed joint research agreement for once-monthly DA-1726 formulation; out-licensed NB-01 for painful diabetic neuropathy."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208933,"accession_number":"0001558370-24-011984","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroBo completes SAD Part 1 enrollment for obesity drug DA-1726; no issues, top-line data Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["45 participants enrolled across 5 cohorts in SAD Part 1 of Phase 1 trial for DA-1726 (GLP1R/GCGR dual agonist).","No significant issues; accelerated start to MAD Part 2 dosing began June 2024.","Top-line SAD data expected Q3 2024; MAD top-line data Q1 2025.","Pre-clinical data showed superior weight loss vs semaglutide and survodutide, comparable to tirzepatide.","Part 3 IND update planned; first patient dosing Q3 2025, interim data mid-2026, top-line H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208932,"accession_number":"0001558370-24-010964","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroBo signs joint research agreement for once-monthly obesity therapy DA-1726","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with Dong-A ST and ImmunoForge to develop long-acting formulation of GLP1R/GCGR dual agonist DA-1726.","ImmunoForge's ELP platform can extend drug half-life up to 200x, enabling once-monthly injection.","DA-1726 currently in Phase 1; financial terms of the agreement not disclosed.","Goal is to improve patient compliance and ease of administration for obesity treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208931,"accession_number":"0001558370-24-010321","cik":1638287,"company_name":"MetaVia Inc.","ticker":"MTVA","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"NeuroBo licenses NB-01 to MThera Pharma for diabetic neuropathy; terms undisclosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license grants MThera rights to develop and commercialize NB-01 for painful diabetic neuropathy.","MThera may conduct a Phase 3 trial in the U.S. and South Korea; NeuroBo to focus on DA-1726 and DA-1241.","Phase 2 efficacy data cited by MThera; financial terms not disclosed.","NeuroBo CEO says deal reflects commitment to out-license legacy assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":15596397.580838325,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-07-30T23:59:59+00:00|208931"}